Hyundai Bioscience Co., Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was KRW 41.3 million compared to KRW 43.36 million a year ago. Net income was KRW 1,185.33 million compared to net loss of KRW 2,096.82 million a year ago.

Basic earnings per share from continuing operations was KRW 30 compared to basic loss per share from continuing operations of KRW 53 a year ago. Basic earnings per share was KRW 30 compared to basic loss per share of KRW 53 a year ago.